Most studies suggest that ACPA positive patients with RA are more likely to have a favorable long term outcome of treatment with the CTLA4-based bDMARD abatacept compared to ACPA negative patients (121, 123, 124). This evidence concerns the gene PRTN3 and rheumatoid arthritis.